it

[ASAP] Structural Fingerprints of an Intact Monoclonal Antibody Acquired under Formulated Storage Conditions via <sup>15</sup>N Direct Detection Nuclear Magnetic Resonance

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00231




it

[ASAP] Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00245




it

[ASAP] Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00021




it

[ASAP] Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00442




it

[ASAP] Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00337




it

[ASAP] Discovery of <italic toggle="yes">N</italic>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<italic toggle="yes">H</italic>-pyrrolo[2,3-<italic toggle=&q

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00628




it

[ASAP] Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00082




it

[ASAP] Ruthenium(II) Complex Containing a Redox-Active Semiquinonate Ligand as a Potential Chemotherapeutic Agent: From Synthesis to <italic toggle="yes">In Vivo</italic> Studies

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00431




it

[ASAP] Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00192




it

[ASAP] Exploration of the Structural Space in 4(3<italic toggle="yes">H</italic>)-Quinazolinone Antibacterials

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00153




it

[ASAP] Discovery and Optimization of Glucose Uptake Inhibitors

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.9b02153




it

[ASAP] Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme

Journal of Medicinal Chemistry
DOI: 10.1021/acs.jmedchem.0c00441




it

[ASAP] Discovery of a Cyclic Choline Analog That Inhibits Anaerobic Choline Metabolism by Human Gut Bacteria

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00005




it

[ASAP] Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00601




it

[ASAP] Chimeric Peptidomimetics of SOCS 3 Able to Interact with JAK2 as Anti-inflammatory Compounds

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00664




it

[ASAP] Progress in the Field of Aldehyde Dehydrogenase Inhibitors: Novel Imidazo[1,2-<italic toggle="yes">a</italic>]pyridines against the 1A Family

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00686




it

[ASAP] Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00118




it

[ASAP] Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00116




it

[ASAP] Glycans Meet Sphingolipids: Structure-Based Design of Glycan Containing Analogues of a Sphingosine Kinase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00665




it

[ASAP] Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00669




it

[ASAP] Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00043




it

[ASAP] Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00045




it

[ASAP] Substituted Naphthalenediimide Compounds Bind Selectively to Two Human Quadruplex Structures with Parallel Topology

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00041




it

[ASAP] Escaping from Flatland: Substituted Bridged Pyrrolidine Fragments with Inherent Three-Dimensional Character

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00039




it

[ASAP] Structure Optimization of Gatastatin for the Development of ?-Tubulin-Specific Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00526




it

[ASAP] Chiral Analogues of PFI-1 as BET Inhibitors and Their Functional Role in Myeloid Malignancies

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00625




it

[ASAP] Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00111




it

[ASAP] Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00681




it

[ASAP] Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00594




it

[ASAP] New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00561




it

[ASAP] Novel Dithiolane-Based Ligands Combining Sigma and NMDA Receptor Interactions as Potential Neuroprotective Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00129




it

[ASAP] Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00574




it

[ASAP] Design and Synthesis of Tetrazole- and Pyridine-Containing Itraconazole Analogs as Potent Angiogenesis Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00438




it

[ASAP] Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00131




it

[ASAP] Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00008




it

[ASAP] Sigma Receptor Ligands Carrying a Nitric Oxide Donor Nitrate Moiety: Synthesis, In Silico, and Biological Evaluation

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.9b00661




it

[ASAP] Characterization of Specific <italic toggle="yes">N</italic>-a-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00029




it

[ASAP] Discovery of an Atropisomeric PI3Kß Selective Inhibitor through Optimization of the Hinge Binding Motif

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00095




it

[ASAP] Can Drug Repositioning Work as a Systematical Business Model?

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00122




it

[ASAP] Update to Our Reader, Reviewer, and Author Communities—April 2020

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00206




it

[ASAP] Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00155




it

[ASAP] Development of Selective Steroid Inhibitors for the Glucose-6-phosphate Dehydrogenase from <italic toggle="yes">Trypanosoma cruzi</italic>

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00106




it

[ASAP] Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00025




it

[ASAP] Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00092




it

[ASAP] Scaffold Repurposing of in-House Chemical Library toward the Identification of New Casein Kinase 1 d Inhibitors

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00028




it

[ASAP] Development of a Raltegravir-based Photoaffinity-Labeled Probe for Human Immunodeficiency Virus-1 Integrase Capture

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00009




it

[ASAP] Substituted Azabicyclo[2.2.1]heptanes as Selective Orexin-1 Antagonists: Discovery of JNJ-54717793

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00085




it

[ASAP] De-risking Drug Discovery of Intracellular Targeting Peptides: Screening Strategies to Eliminate False-Positive Hits

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00022




it

[ASAP] Synthesis and Evaluation of <sup>11</sup>C- and <sup>18</sup>F-Labeled SOAT1 Inhibitors as Macrophage Foam Cell Imaging Agents

ACS Medicinal Chemistry Letters
DOI: 10.1021/acsmedchemlett.0c00127




it

Tanzania turns to solar power to increase electricity connectivity

As many as 60 percent of the Kenyan population now has access to electricity according to official data. But in neighbouring Tanzania, the penetration rate is less than half of that and sparsely populated rural communities are especially neglected.  

The post Tanzania turns to solar power to increase electricity connectivity appeared first on LatestSolarNews.